New Gastrointestinal Bleeding Findings Has Been Reported by Investigators at Hennepin Healthcare Research Institute (Cinacalcet and Gastrointestinal Bleeding Risk In Patients Receiving Hemodial-ysis)

摘要

2021 SEP 21 (NewsRx) - By a News Reporter-Staff News Editor at Disease Prevention Daily - New research on Digestive System Diseases and Conditions - Gastrointestinal Bleeding is the subject of a report. According to news reporting originating from Minneapolis, Minnesota, by NewsRx correspondents, research stated, "Secondary hyperparathyroidism (SHPT) is common among dialysis patients, and calcimimetics are a mainstay of treatment. This study assessed whether cinacalcet use is associated with gastrointestinal bleeding in a large hemodialysis cohort." Financial support for this research came from Amgen. Our news editors obtained a quote from the research from Hennepin Healthcare Research Institute, "A linked database of clinical records and medical claims for patients receiving hemodialysis in a large dialysis organization, 2007-2010, was used. A nested case-control study was performed among patients aged >= 18 years who had received hemodialysis for >= 90 days, had Medicare Parts A, B, and D coverage for >= 1 year, and had clinical evidence of SHPT (parathyroid hormone >300 pg/mL). Cases were those who experienced death or hospitalization caused by gastrointestinal bleeding. Each case was matched to up to four controls. Exposure was measured by any cinacalcet use, current use, past use, cumulative exposure days, and cumulative dosage.